Structurally different RGTAs modulate collagen‐type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor‐2 or transforming growth factor‐β1
Authors:
- 7 May 2004
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 18 (10) , 1147-1149
Abstract
We have engineered polymers called ReGeneraTing Agents (RGTAs), which mimic the protecting and potentiating properties of heparan sulfates toward heparin‐binding growth factors (HBGF). RGTAs have been shown to optimize cell growth and regulate collagen production in vitro. Here, we studied relationships between RGTA structure and collagen‐type expression in aortic smooth muscle cells by using two RGTAs, the carboxylmethylsulfate dextran RG‐1503 and the carboxylmethylsulfate dextran with added benzylamide RG‐1192. RG‐1192 specifically induced a fivefold decrease in collagen III synthesis. This effect was abolished by FGF‐2 neutralizing antibody. RG‐1192 and FGF‐2 acted synergistically to decrease collagen III. RG‐ 1192 was more effective than heparin in this process. RG‐1192 increased the pericellular localization of FGF‐2 and protected FGF‐2 from proteolysis. Surface plasmon resonance analysis indicated a K d of 15.7 nM for the RG‐1192/FGF‐2 interaction (10.6 nM for the heparin/FGF‐2 interaction). The structurally different RG‐1503 (without benzylamide) did not interact with FGF‐2 and worked synergistically with TGF‐β1 to specifically induce a twofold increase in collagen V. RGTAs with different structures exert different modulating effects on the collagen phenotype. Selection of appropriate RGTAs, which had been shown to enhance in vivo tissue repair, may provide a mean of correcting collagen abnormalities in vascular disorders and more generally in fibrotic diseases.Keywords
This publication has 44 references indexed in Scilit:
- Specific RGTA increases collagen V expression by cultured aortic smooth muscle cells via activation and protection of transforming growth factor-β1Matrix Biology, 2001
- New agents for the treatment of infarcted myocardiumThe FASEB Journal, 2000
- Human Plasmin Enzymatic Activity Is Inhibited by Chemically Modified DextransJournal of Biological Chemistry, 2000
- Heparin-Induced Overexpression of Basic Fibroblast Growth Factor, Basic Fibroblast Growth Factor Receptor, and Cell-Associated Proteoheparan Sulfate in Cultured Coronary Smooth Muscle CellsArteriosclerosis, Thrombosis, and Vascular Biology, 1996
- Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakageJournal of Biomedical Materials Research, 1996
- Sulfate Moieties in the Subendothelial Extracellular Matrix Are Involved in Basic Fibroblast Growth Factor Sequestration, Dimerization, and Stimulation of Cell ProliferationJournal of Biological Chemistry, 1996
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Heparan sulphate in the binding and activation of basic fibroblast growth factorGlycobiology, 1992
- Cell density and proliferation modulate collagen synthesis and procollagen mRNA levels in arterial smooth muscle cellsExperimental Cell Research, 1992
- Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGFJournal of Cellular Physiology, 1992